PLoS ONE (Feb 2011)

Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.

  • Kazuma Ohyashiki,
  • Tomohiro Umezu,
  • Sei-Ichiro Yoshizawa,
  • Yoshikazu Ito,
  • Michiyo Ohyashiki,
  • Hisashi Kawashima,
  • Masami Tanaka,
  • Masahiko Kuroda,
  • Junko H Ohyashiki

DOI
https://doi.org/10.1371/journal.pone.0016408
Journal volume & issue
Vol. 6, no. 2
p. e16408

Abstract

Read online

BackgroundWe undertook a study to evaluate the clinical relevance of miR-92a in plasma obtained from non-Hodgkin's lymphoma (NHL) patients, because the miR-17-92 polycistronic miRNA cluster plays a crucial role in lymphomagenesis and affects neo-angiogenesis.Methodology/principal findingsPlasma miR-92a values in NHL were extremely low (Conclusions/significanceThe current results therefore indicate that the plasma miR-92a value could be a novel biomarker not only for diagnosis but also for monitoring lymphoma patients after chemotherapy.